Previous 10 | Next 10 |
Abiomed’s (NASDAQ:ABMD) Impella platform is being featured today at a Washington, D.C., event showcasing innovations in medical technology that improve healthcare for women. Abiomed’s participation supports its Women’s Initiative for Heart Recovery , which provid...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The week ahead sees Apple (AAPL) host its annual WWDC conference, Walmart (WMT) hol...
Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at two upcoming conferences: Jefferies Global Healthcare Conference on Tuesday, June 4, 201...
In a letter to healthcare providers, the FDA states that Abiomed's ( ABMD +2.6% ) Impella RP heart pump is safe and effective for the treatment of right heart failure. More news on: ABIOMED, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Use of early identification protocol leads to higher survival and native heart recovery, as demonstrated in FDA studies In a letter sent to healthcare providers today, the U.S. FDA validates that Abiomed’s (NASDAQ: ABMD) Impella RP heart pump is safe and effective for ...
Improves upon AMI cardiogenic shock historical survival of 50% Abiomed (NASDAQ:ABMD) announces that new data from the National Cardiogenic Shock Initiative Study (NCSI) on 171 consecutive AMI cardiogenic shock (AMICS) patients from 35 sites demonstrates 72% survival with 98% na...
Abiomed (NASDAQ:ABMD) announces today that the Impella CP with SmartAssist , which is designed to improve patient outcomes with advanced algorithms and simplified patient management, will be commercially available beginning at the 2019 Society for Cardiovascular Angiography & Inter...
Abiomed (NASDAQ:ABMD) announces the U.S. FDA has approved the expansion of the Impella 5.0 and Impella LD PMA labeling for the treatment of cardiogenic shock. The expansion extends the duration of support for each pump from 6 days to 14 days. The Impella 5.0 and the Impella LD are f...
Abiomed, Inc. (ABMD) Q1 2019 Earnings Conference Call May 02, 2019, 08:00 ET Company Participants Ingrid Ward - Director, IR Michael Minogue - Chairman, CEO & President Todd Trapp - CFO & VP Conference Call Participants Danielle Antalffy - SVB Leerink Bruce Nudell...
News, Short Squeeze, Breakout and More Instantly...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support...
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 PR Newswire NEW YORK , Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent...
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have...